All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Soignet, Steven ^a   Fleischauer, Aaron ^a   Polyak, Tatyana ^a   Heller, Glenn ^a   Warrell Jr , Raymond P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

All trans retinoic acid; Promyelocytic leukeumia

Indexed keywords

CD33 ANTIGEN; CYTARABINE; HYDROXYUREA; IDARUBICIN; MONOCLONAL ANTIBODY; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CELL STRUCTURE; CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN;

EID: 0030738403     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Berman E, Little C, Kher U, Heller G, McKenzie S, Gee T, Clarkson B (1991) Prognostic analysis of patients with acute promyelocytic leukemia (APL). Blood 78 [Suppl]:43a
2. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR-α/PML proteins. Blood 88:1052
3. 3) in the treatment of acute promyelocytic leukemia (APL): partial differentiation of NB4 and fresh APL cells in vitro and in vivo. Blood 88 [Suppl]:864
4. Dombret H, Sutton L, Duarte M, Daniel MT, Leblond V, Castaigne S, Degos L (1992) Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 6:1237
5. Eardley E, Heller G, Warrell RP Jr (1994) Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 8:934
6. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghein P, Fegueux N, Danici MT, Chomienne C, Dégos L (1992) All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study of 26 cases. Blood 80:2176
7. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Bausters F, Fegueux N, Fey M, Sanz M, Lownberg B, Maloisel E, Dombret H, Chastang C, Degos L, the European APL 91 Group (1993) Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 82:3241
8. Frankel SR, Eardley A, Lauwer G, Weiss M, Warrell RP Jr (1992) The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292
9. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr (1994) All-trans retinoic acid for the treatment of acute promyelocytic leukemia: results of the New York study. Ann Intern Med 120:278
10. Head DR, Kopecky DJ, Wilman C, Appelbaum FR (1994) Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia 8 [Suppl 2]:S38
11. Hughes TP, Morgan GJ, Martiat P, Goldman JM (1991) Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77:874
12. Jurcic JG, Caron PC, DeBlasio A, Dumont L, Warrell RP Jr, Scheinberg DA (1995) Targeted therapy with humanized anti-CD33 monoclonal antibody (HuM195) reduces residual disease in acute promyelocytic leukemia. Blood 86:517a
13. Jurcic JG, Neller WH, DeBlasio A, Scheinberg DA, Warren RP Jr (1996) Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 88 [Suppl]:2529
14. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT Jr, Cork A, Trujillo JM, Freireich EJ (1986) Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 80:789
15. Lo Coco L, Diverio D, Avvisati G, Luciao A, Biondi A, Mandelli G (1995) High frequency of early molecular remission in acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (Italian GIMEMA-AIEOP "AIDA" trial). Blood 86 [Suppl]:1048
16. Mayer RJ, Schaffer CA, Peterson BA, Budman DR, Silver RT, Raik R, Cornwell CG, Ellison RR, Maguire M, Berg DT, Davis RB, McIntyre OR, Frei E III (1987) Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-c: a progress report from the CALGB: Cancer and Leukemia Group B. Semin Oncol 14 [Suppl 1]:25
17. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, DeBlasio A, Levine K, Evans RM, Dmitrovsky E (1992) Reverse transcriptase/ polymerase chain reaction amplification for PML/RAR-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694
18. Peruzzi D, DeBlasio T, Warrell RP Jr, Pandolfi PP (1996) Highly sensitive RT-PCR assay for detection of minimal residual disease in acute promyelocytic leukemia. Blood 88 [Suppl]:1452
19. Rivi R, Calleja E, Konig A, Lai L, Gambacorti-Passerini C, Scheinberg D, Gabriloze JL, Warrell RP Jr, Pandoisi PP (1996) Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on APL and other myeloid and lymphoid leukemia derived cell lines. Blood 88 [Suppl]:260
20. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112
21. Stone RM, Mayer RJ (1990) The unique aspects of acute promyelocytic leukemia. J Clin Oncol 8:1913
22. Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ (1988) Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction theapy: experience in 34 patients. Blood 71:690
23. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843
24. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabriloze J, Gordon M, Dmitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia. N Engl J Med 324:1385
25. Warrell RP Jr, Thé H de, Wang Z-Y, Degos L (1993) Acute promyelocytic leukemia. N Engl J Med 329:177
26. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR (1994) Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 8:929